Page | 1 www.accuscriptspharmacy.com April 2016
Another Successful Educational Event
AccuScripts Pharmacy sponsored and hosted a Lunch & Learn for those who work
with Individuals with Intellectual/Developmental Disabilities (IID). Allisha
Berendts, Licensed Professional Clinical
Counselor and PhD candidate from The Ohio
State University Nisonger Center delivered an
excellent overview of mental health issues in the
IID community and how those present similarly
and differently from the rest of the population.
Attendees from all over northern Ohio were able
to enjoy this event and earn 1 CEU in nursing
and/or Ohio Department of DD training credit.
Evaluations show an excellent response to the
content, speaker and enthusiasm for more similar
topics. Rest assured AccuScripts has heard and
will be offering quality educational programs
like this in the future. As with our pharmacy
operations, your feedback drives our service.
IN THIS ISSUE:
Dementia Incidence in the U.S. 2
Overview of Alzheimer’s Disease 2
Questionable Medication Benefit in
Advanced Dementia 5
Antibiotic Stewardship in LTCF 6
Two Diabetes Drugs have Heart Failure
Risk 7
New FDA Approvals 7
Page | 2 www.accuscriptspharmacy.com April 2016
The March 2016 edition of Annals of Long-Term Care reveals from the first study to look at
dementia risk in the U.S. population that there appears to be dementia incidence highest among
African Americans and American Indians and Alaskan natives; intermediate among Latinos,
Pacific Islanders and Caucasians, and lowest among Asian Americans. This information was
published by The Journal of the Alzheimer’s Association and analyzed data from more than
274,000 northern California members of Kaiser Permanente.
The researchers used electronic health records covering patient visits for a 14 year period – from
January of 2000 through December of 2013 – to identify participants diagnosed with dementia as
well as their race and ethnicity. The dementia diagnoses included Alzheimer’s, vascular and
non-specific dementia.
If a U.S. resident remains dementia-free at age 65, the chances of developing dementia over the
course of the remainder of his / her life is still high. 38% African Americans, 35% American
Indians/Alaskan Natives, 32% Latinos, 30% Caucasians, 28% Asian Americans and 25% Pacific
Islanders can still expect to contract some form of dementia during their remaining years.
Heather S Anderson, MD, staff neurologist and associate professor, University of Kansas
Alzheimer’s Disease Center, and Jasvinder Chawla, MD, Chief of Neurology, Hines veterans
Affairs Hospital, Loyola University Medical Center, have just now published an up-to-date
comprehensive overview of the current information available pertaining to Alzheimer’s:
Alzheimer’s is an acquired disorder of cognitive and behavioral impairment, is progressive and
incurable; the disorder develops due to the formation of plaques in the hippocampus which
hinders and eventually destroys functioning of memory, decision-making, learning and thinking
in general. The plaque formation is still an unknown regarding it being a product of the disease
or the causative agent. It is thought that specific regions of the brain (e.g. entorhinal cortex,
hippocampus) probably begin to be affected some 10-20 years before any visible symptoms
appear. A patient with preclinical AD may appear completely normal on physical examination
and mental status testing.
Mild Alzheimer disease can include:
memory loss
confusion about the location of familiar places
increased time required to complete normal, daily tasks
trouble handling money and paying bills
compromised judgement and declining decision-making
Page | 3 www.accuscriptspharmacy.com April 2016
loss of spontaneity
mood and personality changes; increased anxiety
Moderate Alzheimer disease:
increasing memory loss and confusion
shortened attention span
problems recognizing familiar people
difficulty with language, reading, writing, math
difficulty organizing thoughts and thinking logically
inability to learn new concepts or cope with new or unexpected situations
restlessness, agitation, anxiety, tearfulness, wandering, especially during the late
afternoon or at night
exhibiting of hallucinations, delusions, suspiciousness or paranoia, irritability
loss of impulse control
having perceptual-motor problems e.g. getting out of a chair, setting the table
Severe Alzheimer disease:
inability to recognize anyone
inability to communicate in any way
showing total loss of sense of self
(usually) weight loss
possible onset of seizures, skin infections, dysphagia
only vocalization becomes groaning, moaning or grunting
increased sleeping, with often times progression to bedridden status
incontinence
eventually, death (which is often the result of other illnesses, frequently aspiration
pneumonia)
Diagnosis:
Clinical exam – the clinical diagnosis is usually made during the mild stage of the disease, using
the above-listed signs/symptoms lumbar puncture (which usually reveals elevated levels of tau
and phosphorylated tau in the CSF and amyloid levels are low – this technique is not
recommended now except in research settings) imaging studies of the brain, especially to
differentiate and rule out potentially treatable causes of progressive cognitive decline e.g. chronic
subdural hematoma, normal-pressure hydrocephalus.
Management of Alzheimer’s Disease:
Front line medications (which only slow the rate of progressive symptoms) which are the
neurotransmitter modulators of acetylcholine and glutamate; currently four such modulators have
Page | 4 www.accuscriptspharmacy.com April 2016
been approved and are available on the American market place: Aricept, Exelon, Razadyne and
Namenda.
Other psychoactive medications may be considered to treat the secondary symptoms of AD:
antidepressants
anxiolytics
antiparkinsonian agents
beta blockers
anti-epileptic drugs
neuroleptics (but only when behaviors threaten others, self or property)
Prevention:
No proven modalities, but some epidemiologic studies suggest that the following may be
protective:
physical and mental activity – ongoing
exercise – ongoing
cardiorespiratory fitness – ongoing
(possibly) diet…. the most notable being the Mediterranean diet
Background and risk factors:
Alzheimers is the most prevalent form of dementia in the U.S., affecting over 5.3 million
residents
Extremely costly to the American economy; those with Alzheimer’s aged 65 and over
cost well over 220 billion dollars annually. Approximately 200,000 people younger than
65 with AD constitute the younger demographic.
Currently, an autopsy or brain biopsy is the only way to make a definitive diagnosis of
AD. In clinical practice, the diagnosis is usually made on the basis of the patient’s
history and findings on the Mental Status Examination.
Four different genes (at least) have been definitively associated with AD, and others that
have a probable role have been identified.
The mechanisms by which altered amyloid and tau protein metabolism, inflammation,
oxidative stress and hormonal changes may produce neuronal degeneration in AD are
being elucidated, and rational pharmacologic interventions based on these discoveries are
being developed
The risk factors of obesity, insulin resistance, vascular problems, dyslipidemia,
hypertension (especially midlife), inflammatory markers, Down syndrome, traumatic
brain injury, family history, advancing age, having the APOE 4 genotype and having
decreasing estrogen levels (i.e. being postmenopausal) include many of the risk factors
that place the adult into a mildly compromising situation regarding increasing the odds of
one day presenting with AD.
Page | 5 www.accuscriptspharmacy.com April 2016
The cause / etiology of AD is unknown, however, several investigators now believe that
converging environmental and genetic risk factors trigger a pathophysiologic cascade
that, over decades, leads to Alzheimer pathology and dementia.
As we have just reviewed in the ‘Severe Alzheimer disease’ stage of progression, many, if not all
‘advanced dementia’ descriptions would closely parallel this status described in the severe or end
stage of Alzheimer’s. Upon the arrival to this near-end-of-life state, a very important and often
controversial question needs to be asked and assessed: what medications now should be
discontinued and which ones retained? All kinds of factors now will play a role in determining a
decision as to what meds we keep on board and those we don’t. First and foremost would be the
wishes and desires the resident had in mind at an earlier time when cognitive function was intact
(though this specific area of level of care may well not have been documented in the ‘advance
directives’ section of his/her chart). If no such documentation expressly written by the resident
exists, then the medical power of attorney may need to come up with some kind of medication
regimen guidance and relay this to the PCP, nurse practitioner or P.A. But again, an informed
decision on the part of the MPOA may not be at hand, and he / she may actually feel very ill at
ease in making this decision. If the MPOA turns out to be a family member who communicates
regularly with several other family members, this issue may become a hotly contested decision
with emotion often times entering in to the decision-making process rather than informed logic.
We could examine all classes of medications that might be questionable for continuing
administration to the advanced dementia patient, however, this would be an extremely lengthy
project and the continuing or discontinuing of medications may depend on the unique physical
and / or mental status of the resident in question.
The American Geriatrics Society fosters the idea of minimizing or eliminating medications that
do not support the primary goal of healthcare that should have been or presently needs to be
elucidated for the advanced dementia resident. The Choosing Wisely initiative and campaign
which has published “Ten Things Physicians and Patients Should Question” does list two med
classes and a procedure that should generally be excluded in caring for the end stage dementia
resident. They are:
-the cognitive enhancers (Aricept, Exelon, Razadyne, Namenda) with the rule of thumb being:
these should not be prescribed or continued to manage the end-stage dementia patient without
periodic assessment (perhaps at two to three month increments) of a perceived cognitive benefit
the resident is experiencing + assessing that no adverse gastrointestinal effects are present.
Another class of medications Choosing Wisely, Consumer Reports and AMDA discusses is the
statins. All seem to agree that the vast majority of residents > 75 years of age should not be on
statins – there is no clear evidence for older patients that high cholesterol leads to heart disease
and death, and some studies indicate that older people with the lowest cholesterol levels actually
Page | 6 www.accuscriptspharmacy.com April 2016
have the highest risk of death. Statins generally are somewhat costly, may induce risk factors
such as memory loss, confusion, nausea, constipation, diarrhea and have negative effects on
skeletal muscles when combined with other medications.
And finally the third ‘don’t’ consists of not recommending percutaneous feeding tubes in
patients with advanced dementia; instead offer oral assisted feedings. Multiple studies have
turned in strong evidence that artificial nutrition does NOT prolong life or improve quality of
life in patients with advanced dementia, nor does it ensure comfort or reduce suffering and may
cause fluid overload, diarrhea, abdominal pain, does not promote human interaction and may
increase the risk of aspiration.
Recent overtures expressed by the Center for Medicare and Medicaid Services (CMS) and the
Center for Disease Control and Prevention (CDC) has resulted in heightened awareness and
stricter enforcement of antibiotic stewardship in extended-care facilities across the United States.
LTC facilities are increasingly being cited for inappropriate antibiotic use. A significant
percentage of antibiotics prescribed in facilities have been found to be unnecessary or
inappropriate. In fact, in skilled nursing facilities, the inappropriate use of antibiotics has a
specific guideline (F-Tag 329 Unnecessary Drugs).
In September 2015, the CDC had a press release that advised all nursing homes to implement the
following core elements to improve antibiotic use: leadership commitment, accountability, drug
expertise, action, tracking, reporting and education. These suggestions come after findings that of
the 4.1 million Americans who reside in nursing homes annually, 70% received antibiotics
F329
Medication Issues of Particular Relevance: All Antibiotics
Indications
Use of antibiotics should be limited to confirmed or suspected bacterial infection
Adverse Consequences
Any antibiotic may cause diarrhea, nausea, vomiting, anorexia and hypersensitivity/allergic
reactions
Antibiotics are non-selective and may result in the eradication of beneficial microorganisms
and the emergence of undesired ones, causing secondary infections such as oral thrust, colitis,
and vaginitis.
Page | 7 www.accuscriptspharmacy.com April 2016
during a year and up to 75% of antibiotics are prescribed incorrectly (wrong drug, dose, duration
or reason). The CDC recommendations aim to help nursing homes reduce their inappropriate
antibiotic therapy use to protect residents from the consequences of antibiotic resistant infections
such as C. difficile.
The CDC’s input that is expected to be followed by extended-care facilities and will be
monitored by the various states’ departments of health (who employ long-term care surveyors)
consist of the following:
-healthcare facilities are to direct their health care providers to improve antibiotic use by
prescribing antibiotics correctly. This consists of:
-starting the right antibiotic promptly
-at the right dose
-for the right duration
-reassessing the prescribed antibiotic within 48 hrs based on tests or patient exam
-rechecking prescribing documentation re: dosage, duration and indication
The final guidance mandates the healthcare provider to remain aware and up-to-date regarding
antibiotic resistance patterns within the facility and to oversee that the facility has put into place
an Infection Prevention and Control Officer.
As of April 6, 2016, the U.S. Food and Drug Administration (FDA) has issued a new alert about
the potential for increased heart failure risk in patients taking the D.M.-II medications,
saxagliptin (Onglyza) and alogliptin (Nesina). The bulletin states there may be even a higher
risk for patients taking one of these two drugs who already have cardiovascular or kidney
disease. The notification concludes that clinicians should consider discontinuing medications
containing saxagliptin or alogliptin in patients who develop heart failure and assess the
possibility of changing the medication regimen to a safer glucose-lowering agent. Two related
medications, Tradjenta and Januvia, are not mentioned and remain as AccuScripts Pharmacy’s
preferred DPP-4 inhibitors.
The US Food and Drug Administration has just approved a maintenance drug for adults with
severe asthma who keep having attacks despite treatment with other asthma medications. The
new drug, reslizumab (Cinqair by Teva Pharmaceuticals) is a monoclonal antibody which is
indicated as an adjunct to other asthma drugs for adults (18 and over) whose condition is linked
to elevated eosinophils, a type of white blood cell that can cause airway inflammation. The
FDA estimates that about 5% of all asthmatics have severe and an often uncontrolled version of
the illness despite maximum therapy. Patients receive reslizumab q 4 weeks by I.V. infusion in a
Page | 8 www.accuscriptspharmacy.com April 2016
clinical setting prepared to manage anaphylaxis which is one possible adverse outcome from
receiving this medication.
Dalvance (dalbavancin by Allergan) is a new single-dose injection indicated for the treatment of
adult patients with acute bacterial skin and skin structure infections caused by susceptible
isolates of gram positive staph and strep microorganisms and enterococcus faecalis. Dalvance is
to be administered IV as one dose (1500mg) over 30 minutes or as 1000mg X 1 plus 500mg one
week later. A moderately reduced dosage is recommended in patients with reduced renal
clearance (less than 30ml’s/min) who are not on hemodialysis but NO dosage decrease is
necessary for patients on regularly scheduled hemodialysis.
Feels like the pharmacy “right around the corner.”
Our marketing & sales team who both
makes the promises and produces the service:
Denis Holmes, Executive Vice President [email protected]
Craig Baughman, Director of Pharmacy [email protected]
Sarah Partlo, Director of Financial Accounts [email protected]
Matt Lengauer, Director of Customer Service [email protected]